Compound Radar

Viatris Inc. (VTRS) Stock Analysis

Price $16.61
Market cap $19.08B
Next earnings Nov 5, 2026
Entry status Wait

Last updated Sep 8, 2026

Health Check

Last analyzed Sep 7, 2026

43
43/100 Avoid
  • Financial Health 30
  • Profitability 30
  • Business Quality 60
  • Balance Sheet 55
  • Cash Flow 45

Why this rating?

Health 43/100 — Avoid

Strongest Business Quality 60/100
Softest Profitability 30/100
Wait

Entry timing is weak right now. Quality may be fine; the setup is not.

Company overview

Viatris Inc. (VTRS) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector. Compound Radar rates Viatris Inc. 43/100 (Avoid) due to solid business quality, steady revenue growth, and elevated leverage.

Investment profile

  • Quality Moderate
  • Growth Moderate
  • Balance Sheet Stretched
  • Valuation Attractive

Financial highlights

Valuation

  • Forward P/E 6.22
  • PEG 1.05
  • EV/Revenue 2.14

Profitability

  • Revenue Growth 4.9%
  • Gross Margin 40.3%
  • Operating Margin 12.6%
  • Net Margin -2.8%
  • ROE -2.8%

Financial strength

  • Cash $1.51B
  • Debt $13.62B
  • Net Cash $-12.11B
  • Free Cash Flow $1.85B
  • Current Ratio 1.59

Similar companies

Peers in Drug Manufacturers - Specialty & Generic, ranked by Financial Health.

Company Ticker
Price Current price

Latest quoted price for the name. Helps anchor the setup in today’s market level.

Health Entry

View all in Drug Manufacturers - Specialty & Generic →

FAQ

How Compound Radar scores and tracks Viatris Inc. (VTRS).

View Methodology & FAQ →